Background. Mycoplasma pneumoniae strains with resistance to macrolides have been spreading worldwide. Here, we aimed to clarify which antimicrobial agent is a better treatment for patients with M. pneumoniae pneumonia in a setting with large epidemics of macrolide resistance.
Japan [10] . Baseline patient information includes age, sex, primary diagnosis, and comorbidities at admission, coded using the International Classification of Diseases, 10th Revision (ICD-10) [11] . The database also includes the dosages and dates of administration of all drugs, including antimycoplasmal agents and other antibiotics, and blood products administered during admission. All interventional procedures were decoded from the original Japanese codes. Dates of admission and discharge, bedside procedures, drugs administered, and status at discharge (dead or alive) were recorded using a uniform data submission format. The DPC is an administrative database with information on inpatients input at discharge. Thus, for this study, patient follow-up began from the day of admission and ended on the day of discharge from the hospital, transfer to other hospitals, or death. It was impossible to investigate an outpatient treatment before admission and to follow up patients after discharge since this was beyond the scope of the database.
Data were anonymized by stripping all personally identifiable information during extraction and analyzed within the protected environment of the Nagasaki University Hospital. The need for informed consent was waived by the Nagasaki University Hospital (Nagasaki, Japan) Institutional Review Board, which also approved the study design.
Patient Selection
We identified hospitalized patients with laboratory-confirmed M. pneumoniae pneumonia from January 2010 to December 2013. During this period, there were multiple large epidemics of M. pneumoniae infections, and the prevalence of macrolide-resistant M. pneumoniae in Japan was reported to be more than 80% [5, 7, 8, 12] . We included patients who were aged ≥18 years and who had undergone diagnostic testing (paired antibody titers, polymerase chain reaction, and antigen detection) to confirm M. pneumoniae infection. In many cases, antibodies to M. pneumoniae were measured using the passive agglutination test, which is a more advanced alternative to the complement fixation test [13] . Single measurements of antibody titer and cold agglutinin tests were not included as diagnostic tests in this study because those are not specific tests for M. pneumoniae infection. We restricted the analysis to adults because of limitations in the use of quinolones and tetracycline in children [1] .
Exclusion criteria included the following: discharge within 2 days of admission, use of multiple antimicrobial agents within 2 days of admission, no use of any antimicrobial agent within 2 days of admission, and use of antimicrobial agents for <3 days. We eventually recruited patients who were started on single antimicrobial agents within 2 days of admission and treated for more than 3 days.
Variables and Endpoints
Comorbidities were evaluated using the Charlson comorbidity index (CCI), a method of predicting mortality by classifying or weighting comorbidities [11] . The CCI has been widely used by health researchers to measure the case mix and burden of disease. The CCI includes 17 conditions with major impact on survival. A higher CCI score reflects the presence of severe comorbidities. The Japan coma scale (JCS) was used to assess the level of consciousness for all patients at admission. This score is categorized into 4 groups: 0 (alert), 1-3 (delirium), 10-30 (somnolence), and 100-300 (coma). A JCS score of 100 is equivalent to a Glasgow coma score of 6-9 [14] . We assessed all medications administered and interventions performed within 30 days of admission.
The endpoints measured were switching to another antimycoplasmal agent, the length of stay (LOS), all-cause 30-day mortality, and total costs of all drugs used, including antimycoplasmal agents and all other prescribed drugs. We defined switching to another antimycoplasmal agent as the administration of an agent that was different from the first-line agent upon cessation of the initial one after 5 days of admission.
Statistical Analyses
Fisher exact or Pearson χ 2 test was used to compare discrete variables; analysis of variance was used to compare the means of continuous variables in several groups simultaneously; and the t test was used to compare the difference between the mean of 2 groups. To compare the efficacies of quinolone and tetracycline therapy, we performed a 1-to-1 matching between the group that started treatment with quinolones and those who started treatment with tetracycline based on the estimated propensity scores for each patient in order to minimize the bias due to confounding variables [15] . We compared the quinolone group with the tetracycline group but not with the macrolide group because we assumed that most study patients had macrolide-resistant M. pneumoniae infections.
To estimate the propensity score, we fit a logistic regression model for starting treatment with quinolone as a function of patient demographics that included age, sex, CCI, and each comorbidity included in the CCI (myocardial infarction, congestive heart failure, peripheral vascular disease, cerebrovascular disease, dementia, chronic pulmonary disease, rheumatic disease, peptic ulcer disease, mild liver disease, diabetes without chronic complications, diabetes with chronic complications, renal disease, any malignancy, moderate or severe liver disease, metastatic solid tumor). Other parameters used included the JCS score, the use of other supportive drugs (catecholamines, immunoglobulin, sivelestat sodium), blood-product transfusion (red blood cells, platelets, fresh frozen plasma), interventions (hemodialysis, invasive ventilation, noninvasive ventilation), and admission to the intensive care unit [14] . Catecholamines used included dopamine, dobutamine, and noradrenaline (norepinephrine). A 1-to-1 matched analysis using nearest-neighbor matching was performed based on the patients' estimated propensity scores. A match was said to have occurred when a patient in the quinolone group had an estimated score within 0.2 standard deviations of a patient in the tetracycline group [16] . We examined the balance in baseline variables using standardized differences, where >10% was regarded as imbalanced [17] .
To identify factors that influenced the switching of antimycoplasmal agents, we performed multivariable logistic regression analyses for all patients, macrolide-treated patients, quinolonetreated patients, and tetracycline-treated patients who needed a change of agents, adjusting for selected characteristics with statistically significant differences. Odds ratios (ORs) and their 95% confidence intervals (CIs) were then calculated. All statistical analyses were performed using JMP 12.0 software (SAS Institute, Cary, North Caroline). All tests were 2-tailed, and a P value < .05 was considered to be statistically significant.
RESULTS

Patients
A total of 2718 patients were admitted with M. pneumoniae pneumonia to 690 hospitals during the 4-year study period. Among them, 2390 patients were diagnosed by paired antibody titers, 213 by polymerase chain reaction, and 153 by antigen detection ( Figure 1 ). Overall, 1068 patients were excluded based on the various exclusion criteria previously mentioned. No patients died within 2 days of admission. The remaining 1650 patients from 602 hospitals were divided into 3 groups: those who started treatment with a macrolide (n = 508), with a quinolone (n = 569), and with a tetracycline (n = 573). A breakdown of the drugs used within each group is shown in Supplementary Table 1. Descriptive statistics for all patients are presented in Table 1 . When the 3 groups were simultaneously compared, patients who were treated with quinolone had more complex comorbidities; the number of patients with altered sensorium was highest in the tetracycline group; patients within the quinolone group tended to require more supportive drugs, more blood-product transfusion, more mechanical ventilation, and more admissions to the intensive care unit. The total duration of antimicrobial treatment including switched agents was 7.8 ± 4.8 days for patients in the macrolide group, 9.1 ± 4.7 days for patients in the quinolone group, and 8.7 ± 4.2 days for patients in the tetracycline group, which showed a statistically significant difference (P < .0001).
Outcomes
The proportion of patients who were switched to other antimycoplasmal agents was significantly different among the 3 groups (P < .0001; Table 2 ). The switches occurred as follows: macrolide to quinolone (42.5%), quinolone to macrolide (15.5%), and tetracycline to quinolone (25.1%). The duration of first-line treatment until the switch was 3.1 ± 3.0 days for patients in the macrolide group, 8.0 ± 4.7 days for patients in the quinolone group, and 6.9 ± 3.3 days for patients in the tetracycline group, which showed a statistically significant difference (P < .0001). LOS was longest in the macrolide group (18.5 ± 22.8 days) and shortest in the tetracycline group (15.9 ± 20.07 days), though this difference was not significant (P = .0995). There was no difference in the 30-day mortality among the 3 groups (P = .5472). The total cost of all drugs used during hospitalization was highest in the quinolone group and lowest in the tetracycline group (P = .0062).
From the quinolone and tetracycline groups, 487 propensity score-matched pairs were generated (Figure 1 ). After propensity score matching, the baseline patient characteristics were well balanced between the quinolone and tetracycline groups since all standardized differences were <10%. The total duration of antimycoplasmal treatment was almost equal in both quinolone (8.9 ± 4.6 days) and tetracycline groups (8.6 ± 4.0 days; P = .2736). The proportion of patients who were switched to other antimycoplasmal agents was lower in the quinolone group than in the tetracycline group (21.2% vs 39.6%, P < .0001; Table 3 ). There were no significant differences in the LOS, 30-day mortality, and total cost of all drugs between the 2 groups (P = .7963, P = 1.0000, and P = .3519, respectively).
Characteristics of Patients Who Needed to be Switched to Other Antimycoplasmal Agents
A logistic regression analysis adjusting for parameters showed statistically significant differences in all characteristics of all patients (Supplementary Table 2 ) and revealed that the selection of a macrolide as first-line therapy was a major factor that necessitated a change to other antimycoplasmal agents when compared to the quinolone group (OR, 4.2; 95% CI, 3.2-5.5; P < .0001; Table 4 ). Treatment with tetracycline also showed a high OR against quinolone treatment (OR, 2.4; 95% CI, 1.8-3.1; P < .0001). For patients treated with macrolides, only males showed a statistical difference between those who were switched to another antimycoplasmal agent and those who were maintained on macrolides. For patients treated with a quinolone, congestive heart failure, diabetes with chronic complications, solid metastatic tumor, or hemodialysis were factors associated with switching of antimycoplasmal agents. Interestingly, for diabetic patients within the tetracycline group, those who had chronic complications had higher odds (OR = 6.8) of being switched to another antimycoplasmal agent compared to those without chronic complications (OR = 0.4; Table 4 ).
DISCUSSION
In this study we assessed the efficacy of macrolide, quinolone, and tetracycline therapies in hospitalized adult patients with M. pneumoniae pneumonia in an area with large epidemics of macrolide-resistant M. pneumoniae infections. In the case of macrolide-resistant M. pneumoniae strains, another choice of antimicrobial treatment may be required, including quinolones and tetracyclines. Quinolone and tetracycline regimens have been reported to be more effective than macrolide regimens in patients infected with macrolide-resistant M. pneumoniae [8, 18, 19] . However, macrolides appear to be clinically effective in some patients infected with macrolide-resistant strains [20] [21] [22] . This observation can be explained by the fact that M. pneumoniae infections are often self-limiting and that the antiinflammatory effects of macrolides may contribute to the Data are shown as n (%) or mean ± standard deviation. Data are shown as n (%) or mean ± standard deviation. Catecholamines include dopamine, dobutamine, and noradrenaline. Acquired immune deficiency syndrome, which was evaluated using Charlson comorbidity index, was excluded from this table because there were no patients with this disease.
improvement in clinical symptoms [1] . These conflicting results made it more challenging to determine the most suitable regimen for M. pneumoniae infections in an area with large epidemics of macrolide-resistant M. pneumoniae infections. Therefore, clinical studies that include a large number of patients were required to clarify this. We resolved this by using a large nationwide administrative database that spanned several years. Our study revealed that more than half of the patients treated with macrolides needed to be switched to other antimycoplasmal agents and required a slightly longer period of admission than patients treated with quinolones and tetracyclines. The existence of macrolide-resistant M. pneumoniae infections may affect the results of this study, though no antimycoplasmal susceptibility tests were performed in this study. However, we did not note an increase in mortality rates, which might indicate that a delay in selecting a suitable antimycoplasmal treatment could be recovered by switching to suitable agents within an average of 3.1 days after the first macrolide administration despite prolongation of hospitalization, which can be a favorable result for children for whom there is a limitation in the use of quinolones and tetracycline.
It is important to determine whether quinolone or tetracycline is better against M. pneumoniae pneumonia if macrolides cannot be used for some reason. Okada et al reported that tetracycline might be superior to quinolones in more quickly decreasing numbers of M. pneumoniae DNA copies in nasopharyngeal samples [8] . This result seems to indicate that the use of a tetracycline regimen could shorten the LOS compared to the use of a quinolone regimen. However, our study revealed that the LOS for patients in both the tetracycline and quinolone groups did not differ. Additionally, the odds of switching to other agents were surprisingly higher in the tetracycline group than in the quinolone group. Although we could not analyze reasons for switching agents in this study, it may have been due to no clinical improvement or to adverse effects of the initial regimen. Moreover, no studies have compared the adverse effects of tetracycline and quinolone therapy in adult hospitalized patients with M. pneumoniae pneumonia. However, it has been reported that tetracycline use results in digestive and skin disorders and headaches, which often necessitate switching of medication [23] . If tetracycline has a better antimycoplasmal effect than a quinolone, the reason for more frequent switching in the tetracycline group may have been the poor tolerance compared to that noted in those using quinolones.
Cost-benefit analysis was also conducted, which is an important factor to consider in selecting a more appropriate agent for the treatment of M. pneumoniae infection. We considered the total cost of all drugs used, including antimycoplasmal agents and all other prescribed drugs, because treatment failure would generate additional costs. Among the 3 groups, the quinolone group showed the highest cost, which might be attributable to the severity of their infection; patients in this group required invasive ventilation more frequently and stayed in the intensive care unit longer than patients in the other 2 groups. If quinolone treatment is more expensive than macrolide or tetracycline treatment, physicians could select a nonquinolone agent as an initial treatment since other variables such as LOS and 30-day mortality showed no significant difference between The odds ratios were adjusted for parameters that showed statistically significant differences from all characteristics of patients. References of start with macrolide and tetracycline were quinolone.
these medications despite the possibility that the outcome of drug switching was different. This study had some limitations. First, the diagnosis of M. pneumoniae pneumonia for most patients depended on paired antibody titers in this study. Therefore, there might have been a selection bias to patients who needed longer hospitalizations. It may be a disadvantage in this analysis for the macrolide-treated group because azithromycin-treated and those who were discharged earlier than those treated with other agents due to its shorter duration of treatment were excluded from this analysis. If those patients were included in the study, the proportion of patients who required switching from macrolides to other antimicrobial agents might have been smaller than the value in the current study. Second, we could not determine the prevalence of macrolide-resistant M. pneumoniae in this study. On the other hand, there was no geographical bias because study patients were selected from various parts of Japan because we used a nationwide database. The larger proportion of patients who needed switching from macrolides to other antimycoplasmal agents might also indicate that many patients had macrolide-resistant M. pneumoniae in this study. Last, although we used a nationwide database, it was retrospective and observational and without randomization. Although we used propensity score matching to adjust for differences in baseline characteristics and disease severity, bias arising from unmeasured confounders, such as complications of other causes of bacterial pneumonia, clinical variables, laboratory values, and pneumonia severity index, may have been present. Large randomized trials are warranted to confirm these, but it may not be easy to perform such trials, considering that this is a rare condition. Thus, the present study may provide the best attainable level of evidence on this issue.
In conclusion, we revealed that macrolide-treated patients more frequently needed to switch agents than patients treated with quinolones or tetracyclines despite the absence of an increase in mortality for hospitalized patients with M. pneumoniae pneumonia in large epidemics of macrolide-resistant M. pneumoniae infections. In addition, patients treated with quinolones had a lower possibility of a switch to other medications than those treated with a tetracycline. However, we have to note the risk of increasing resistance to quinolones if this antibiotic is used inappropriately.
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